Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Quantitative neuroiMaging In early Neurodegenerative Disease

Ziel

Neurodegenerative diseases, including Alzheimer’s disease (AD), pose a major global health and economic challenge, with over 10 million new cases annually and costs exceeding $1.3 trillion. As the first AD-modifying therapies emerge, their effectiveness depends on identifying the right patients at the appropriate stage. However, current diagnostic and clinical trial-support tools, such as PET scans and lumbar punctures, are costly, poorly scalable and have safety risks. This impairs patient stratification and trial efficiency, and delays diagnosis until significant neuronal loss has occurred, limiting treatment impact.

We are developing a quantitative toolkit to enable early detection of AD-related brain changes, before irreversible clinical symptoms develop, allowing timely interventions that prevent disease progression. Our platform transforms routine, widely accessible Magnetic Resonance Imaging (MRI) scans into personalised, population-referenced markers of brain health, building on over a decade of research in advanced brain MRI analytics. Using AI-driven normative models, our approach supports better patient stratification, including selection of individuals likely to respond to therapy, thus improving clinical trial outcomes, and enable early diagnosis.

Within this proof-of-concept, we will: i) consolidate MRI-derived markers of early AD, building upon our pilot evidence, ii) benchmark them against PET and evaluate their predictive power for progressive AD phenotypes, iii) independently validate their performance through industry & clinical partners, iv) devise a commercialisation plan through planned market research. Utilising existing industry links, we will initially focus on enhancing patient selection for AD clinical trials, building the evidence base for regulatory approval and clinical translation. Ultimately, our toolset will be productised to allow emerging clinical care pathways to be optimised, improving patient outcomes and healthcare economics.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

THE UNIVERSITY OF NOTTINGHAM
Netto-EU-Beitrag
€ 150 000,00
Adresse
University Park
NG7 2RD Nottingham
Vereinigtes Königreich
Region
East Midlands (England) Derbyshire and Nottinghamshire Nottingham
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Begünstigte (1)